Pomegra
Australian clinical AI startup Heidi closes $340 million in combined equity and growth financing, reaching a $900 million valuation on the back of 175 million patient visits globally.
- Blackbird led a $100M Series C equity round; General Catalyst's Customer Value Fund contributed a separate $240M growth tranche.
- Annual recurring revenue grew from $1 million to $50 million in 24 months, reaching that milestone by April 2026.
- The platform now processes 2.8 million patient visits weekly across 190 countries and 110 languages.
Lead
Heidi Health, the Melbourne-founded clinical AI company, closed $340 million in new financing on September 22, 2026, split between a $100 million Series C equity round led by Blackbird Ventures and a $240 million growth investment from General Catalyst's Customer Value Fund. The equity tranche values the company at $900 million - just shy of unicorn status, a threshold it has not officially crossed despite the headline. Existing investors Phoenix Court, Point72 Private Investments, and Headline also participated. Heidi says it has now supported more than 175 million patient visits totaling over 67 million clinical hours since its 2021 launch.
What Does Heidi Actually Do?
The company started as an AI medical scribe. Clinicians open a session before an appointment, Heidi listens, and a structured clinical note appears for review. That core workflow won early adoption; ARR scaled from $1 million to $50 million in two years without the marketing spend typical of enterprise health IT. The product now operates in 190 countries across 110 languages, covering general practice, specialist consultations, and hospital settings.
The round is funding a pivot in ambition. Heidi is building what it calls "supervised agentic workflows" - AI systems that take actions beyond transcription, such as drafting referrals, surfacing relevant clinical evidence, and managing administrative follow-through. Heidi Evidence, launched in March 2026, provides context-aware clinical guidelines at the point of care and has already answered more than 10 million queries.
Why Is General Catalyst Structuring This as Growth Financing?
The $240 million tranche is not equity at the same terms as the Series C. General Catalyst deployed it through its Customer Value Fund, a vehicle designed to finance go-to-market scale rather than take pure equity risk. The structure implies Heidi needed capital for expansion velocity - particularly sales and implementation costs as it enters large health systems - without diluting existing holders at current valuations. It is a common mechanism for high-growth SaaS companies with predictable unit economics, though it does add financial obligations if revenue growth slows.
The $900 million equity valuation itself merits scrutiny. At $50 million ARR, that is an 18x revenue multiple - elevated, though not unusual for clinical AI in the current market. Heidi's last disclosed round, a Series B, was not public at the time; the Series C implies meaningful step-up in valuation, which is now partly a bet on the agentic product roadmap rather than the documented documentation business alone.
Market Context
Clinical documentation AI is a crowded space. Competitors including Suki, Nabla, Abridge, and ambient scribe integrations from major EHR vendors are all contesting the same physician attention. Heidi's international footprint - particularly its penetration outside the United States - differentiates it from most domestic US players. Reaching 190 countries at this ARR level with a subscription model suggests a broader addressable market than what US-centric competitors have reported.
The shift toward agentic healthcare AI is where the larger strategic bet sits. If AI agents can reliably execute clinical tasks - ordering tests, coordinating referrals, managing prior authorizations - the addressable revenue per clinician expands substantially. That opportunity also comes with heightened regulatory exposure, particularly in the EU, UK, and Australian markets where medical device and AI safety frameworks are tightening.
What Does the Round Signal for Australian Health Tech?
Heidi was founded in 2019 by Dr. Thomas Kelly, a vascular surgical resident, along with Waleed Mussa and Yu Liu. The company initially traded as Oscer before the 2021 rebrand. Its growth to near-unicorn status on the back of an ambient documentation product - a category that barely existed four years ago - reflects how quickly AI capability has translated into clinical adoption.
Blackbird Ventures now backs one of Australia's most valuable private health tech companies, extending a portfolio that has been constructing positions in applied AI across the region. For Australian founders, the round demonstrates that local healthcare startups can compete for large-ticket institutional capital without relocating to the US.
Outlook
Heidi enters its next phase with enough capital to build out the agentic product, expand its health system sales motion, and defend its international market share. The $900 million valuation carries expectations that require the documentation business to keep growing while a new agentic revenue stream materializes. Regulatory clearance timelines for AI agents in clinical settings add a variable the company cannot fully control. Whether the Customer Value Fund structure ultimately enhances returns or constrains flexibility will depend on how fast health systems are willing to commit.
